Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?

James M. Stone

Ther Adv Psychopharmacol

(2011) 1(1) 5–18

DOI: 10.1177/
2045125311400779

© The Author(s), 2011.
Reprints and permissions:
[http://www.sagepub.co.uk/
journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Abstract: Growing evidence for glutamate abnormalities in schizophrenia support the development of novel antipsychotic agents targeting this system. Early studies investigating modulation of the glutamate system using glycine, D-serine and sarcosine in patients with schizophrenia have demonstrated significant effects, particularly on negative symptoms, conventionally thought to be refractory to antipsychotic drug treatment. Drugs targeting the glutamate system also have a completely different side-effect profile to dopamine D2 antagonists, with no propensity to extrapyramidal side effects, prolactinaemia or weight gain. It has been hypothesized that glutamatergic drugs may be of benefit to the 20–30% of individuals with schizophrenia who fail to show any response to dopaminergic agents, and may be particularly useful in the early stages of the illness, where they may be disease-modifying. A number of glutamatergic compounds have been reported as having promising results in phase II drug trials. If these reach the clinic, they will represent the first truly novel approach to pharmacotherapy in schizophrenia for more than 50 years.

Keywords: schizophrenia, psychosis, pharmacology, antipsychotic drugs, glutamate

Introduction

For more than 50 years, the only effective antipsychotic drugs available have been dopamine D2 receptor antagonists [Kapur and Mamo, 2003], with their clinical potency directly corresponding to their affinity at D2 receptors [Seeman and Lee, 1975]. Despite leading to at least a partial clinical response in around two thirds of patients with schizophrenia, the other third of patients will fail to respond to D2 antagonists [Stone *et al.* 2010b]. Furthermore, although positive symptoms generally show a reasonable response to these drugs, there frequently remains a core of negative symptoms that are refractory to antipsychotic treatment [Javitt, 2001; Buchanan *et al.* 1998; Tamminga *et al.* 1998].

All currently available antipsychotic drugs have significant, and sometimes potentially life-threatening, side effects, which may lead to discontinuation of the treatment. Although the second generation of antipsychotic drugs have a lower incidence of extrapyramidal side effects, they are associated with other debilitating effects such as impaired glucose tolerance and weight gain, which can have significant health

consequences. Thus, there has been a great deal of interest in developing new targets for pharmacological treatment in schizophrenia: drugs which might have fewer side effects and/or lead to response in patients who do not respond fully to currently available drugs [Stone *et al.* 2010b]. So far, the only major advance in drug treatments for schizophrenia has been the discovery of clozapine, which has been consistently shown to have superior efficacy in patients unresponsive to other antipsychotic drugs [McEvoy *et al.* 2006; Kane *et al.* 1988]. No other agent developed since clozapine has shown equivalent efficacy, and improvements over first-generation antipsychotic drugs have been incremental at best. Part of the reason for this lack of rapid progress may be due to the fact that drug development in schizophrenia has primarily focused on the strategy of developing new drugs that act on the dopamine system rather than developing compounds for other targets.

Glutamatergic neurotransmission

Glutamate is the main excitatory neurotransmitter in the brain. Between 60% and 80% of total brain metabolic activity in the nonstimulated cerebral cortex is utilized by glutamatergic

Correspondence to:
James M. Stone
Experimental Medicine,
Imperial College London,
Hammersmith Hospital,
Du Cane Road, London
W12 0NN, UK
[james.m.stone@
imperial.ac.uk](mailto:james.m.stone@imperial.ac.uk)

neurones, with the remainder being used by GABAergic neurones and glial cells. The synaptic release of glutamate and recycling to glutamine in astrocytes is a major metabolic pathway (Figure 1), and accounts for between 80% and 100% of total glutamate trafficking, and it is now accepted that no meaningful distinction can be made between metabolic and neurotransmitter glutamate [Rothman *et al.* 2003].

Glutamate acts at two main subtypes of neuror-eceptor, the metabotropic glutamate receptors (mGluR) and the ionotropic glutamate receptors. mGluR are composed of three groups (groups I–III) distinguished by their sequence homology, pharmacology and second messenger systems. Group I receptors (mGluR1 and mGluR5) are predominantly postsynaptic in somatodendritic domains and couple via G_q/G_{11} to phospholipase C, whereas groups II (mGluR2 and mGluR3) and III (mGluR4, mGluR6, mGluR7 and mGluR8) are coupled via G_i/G_o to inhibition of adenylate cyclase activity and are primarily pre-synaptic in axonal domains and terminals, where they modulate neurotransmitter release [Kew and Kemp, 2005].

Figure 1. Glutamatergic synapse showing glutamate release, binding to AMPA and NMDA receptors on the postsynaptic membrane, and subsequent reuptake by astrocytes where it is metabolized to glutamine by glutamine synthetase (GS).

Ionotropic glutamate receptors are also divided into three groups, named after the agonists originally found to selectively activate them: α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) receptors. The ionotropic glutamate receptors are all heteromeric ion channels, composed of multiple protein subunits. When activated they lead to an increase in cation conductance with differential permeability to Na^+ and Ca^{2+} depending upon receptor type and subunit composition. NMDA receptors in the adult brain generally show increased Ca^{2+} conductance on activation, whereas kainate receptors lead to an increase in Na^+ conductance. AMPA receptors expressed on GABAergic hippocampal and amygdala interneurons appear to lack an edited GluR2 subunit, and show preferential Ca^{2+} conductance, whereas those on pyramidal neurons are non- Ca^{2+} permeable [Kew and Kemp, 2005; Dingledine *et al.* 1999].

NMDA receptor structure and function

The NMDA receptor is a heteromeric ion channel, formed from a number of subunits (NR1, NR2A–NR2D, NR3A and NR3B). NR1 and NR2(A–D) subunits are obligatory for a functional NMDA receptor, and contain binding sites for glycine (glycine_B site) and glutamate respectively. NR2 subunits show distinct regional and developmental distribution, with NR2A and NR2B being expressed primarily in the forebrain, NR2C in cerebellar granule cells and NR2D being expressed during foetal development in the midbrain and diencephalon. NR3 subunits require both NR1 and NR2 subunits to form functional NMDA receptors. NR3A receptors are expressed primarily during development, and NR3B are only found in somatic neurons in brainstem and spinal cord. Activation of the NMDA receptor requires two obligatory co-agonists, binding at the glycine and glutamate sites. Two independent glycine, and two independent glutamate binding sites appear to be required. Therefore, it has been suggested, the minimum requirement for a functional NMDA receptor is two NR1 and two NR2(A–D) subunits [Kew and Kemp, 2005]. At resting potential, NMDA receptors are blocked by extracellular Mg^{2+} , which binds to an intrachannel site of the NMDA receptor complex. In order to allow Ca^{2+} to enter the cell, in addition to glutamate and glycine binding, the cell must depolarize, removing the Mg^{2+} block [Dingledine *et al.* 1999] (see Figure 2). Uncompetitive allosteric

antagonists of the NMDA receptor such as ketamine, phencyclidine (PCP) and dizocilpine (MK-801) bind to the inside of the NMDA receptor ion channel when it is in its open state, and prevent Ca^{2+} influx.

Glutamate and schizophrenia

There is growing evidence that changes in glutamatergic neurotransmission may occur in schizophrenia, and it has been hypothesized that glutamatergic changes may precede, or give rise to, alterations in other downstream neurotransmitter systems such as dopamine [Stone *et al.* 2007]. The glutamate hypothesis of schizophrenia was founded on a number of observations. Drugs that act as uncompetitive antagonists at NMDA receptors such as PCP and ketamine reliably and instantly induce a drug-induced state that closely resembles the symptoms of schizophrenia, including thought disorder, odd ideas and delusions, cognitive impairment and, most notably, an emotional withdrawal that has been likened to the negative symptoms of schizophrenia [Javitt, 2007; Morgan and Curran, 2006; Krystal *et al.* 1994]. In contrast, drugs that increase brain dopamine transmission, such as amphetamine, do not induce cognitive or

negative symptoms [Krystal *et al.* 2005]. Blockade of NMDA receptors by ketamine has been shown to be most closely related to negative, rather than positive symptoms [Stone *et al.* 2008], suggesting that dopamine and glutamatergic changes may give rise to different symptoms of the illness [Stone *et al.* 2008; Krystal *et al.* 2005]. Second, candidate risk genes for schizophrenia are not related to the dopamine system, but rather converge on molecules involved in glutamatergic neurotransmission [Harrison and Weinberger, 2005].

These findings suggest, as hypothesized previously, that negative and cognitive symptoms may be at the core of schizophrenia [Andreasen, 1999]. Cognitive symptoms have been found to be closely associated with negative symptoms in patients with schizophrenia [Ventura *et al.* 2009; Addington *et al.* 1991], and negative symptoms are most closely associated with functional outcome [Ventura *et al.* 2009]. Early and subtle cognitive decline is one of the first (usually undetected) symptoms of schizophrenia [Bilder *et al.* 2006], and it is interesting to speculate that these changes might arise secondary to abnormalities in NMDA receptor function or glutamatergic transmission.

Figure 2. Simplified diagram of an NMDA receptor with glycine (Gly), glutamate (Glu) and MK-801/PCP/ketamine (PCP) binding sites displayed. Extracellular calcium entry through the NMDA receptor occurs only when both glutamate and glycine bind to their respective binding sites, and the cell membrane depolarises allowing removal of the voltage-dependent block due to extracellular magnesium ions binding inside the pore of the NMDA receptor.

Studies of the effect of NMDA receptor antagonists on brain structure and function are supportive of the hypothesis of abnormalities of glutamatergic transmission in schizophrenia. Seminal work by Olney and Farber showed that exposure of rats to systemic injections of NMDA receptor antagonists led to neurotoxic changes in cortical brain regions, which they suggested closely resembled the reductions in grey matter volume seen in patients with schizophrenia [Olney and Farber, 1995]. They showed that antagonists for the AMPA subtype of glutamate receptor blocked this toxicity, and hypothesized that the cortical toxicity was caused, somewhat counterintuitively, by excess cortical glutamate release. They put forward the theory that NMDA receptors expressed on GABAergic interneurons were particularly sensitive to NMDA receptor antagonists and that the resultant reduction in inhibitory tone led to disinhibition of glutamatergic projection neurons leading to glutamate release and excitotoxicity [Olney and Farber, 1995] (Figure 3).

This hypothesis was supported by later microdialysis studies showing increased glutamate in

Figure 3. Hypothesized mechanism whereby NMDA receptor antagonists lead to increased cortical glutamate release: inhibition of NMDA receptors expressed on GABAergic interneurons (A) leads disinhibition of glutamatergic projection neurons (B).

prefrontal cortex following systemic administration of ketamine [Lorrain *et al.* 2003a; Moghaddam *et al.* 1997]. Interestingly, injection of the NMDA receptor antagonist MK-801 into cortical regions did not lead to any evidence of neurodegenerative changes, whereas injection into anterior thalamus led to the same cortical changes as seen with systemic administration [Sharp *et al.* 2001], suggesting that thalamus might be a primary site of NMDA receptor blockade in the generation of downstream effects by NMDA receptor antagonists and, by extension, may also be a site of NMDA receptor dysfunction in schizophrenia [Stone *et al.* 2007; Olney *et al.* 1999].

Studies of patients with schizophrenia and first-episode psychosis, and in individuals with prodromal symptoms of schizophrenia ('at risk mental state' [ARMS]), who are at high risk of developing schizophrenia [Phillips *et al.* 2000], have generally been supportive of the hypothesis of NMDA receptor dysfunction and altered glutamate transmission in the illness [Stone, 2009]. A study using a single photon emission tomography (SPET) ligand for the NMDA receptor revealed that individuals with schizophrenia who were not currently medicated had lower NMDA receptor binding in the left hippocampus compared with healthy volunteers [Pilowsky *et al.* 2006] (Figure 4). This finding was in close agreement with an earlier postmortem study of mRNA of the NMDA receptor subunit NMDAR1, which revealed that patients with schizophrenia showed reduced levels in left

dentate gyrus [Law and Deakin, 2001]. Furthermore, in patients treated with typical antipsychotic drugs, levels of NMDA receptor binding in the left hippocampus were inversely correlated with negative symptoms [Pilowsky *et al.* 2006].

Studies employing proton magnetic resonance spectroscopy (^1H -MRS) have measured cortical glutamate and glutamine levels in individuals at high risk of psychosis, as well as patients with first-episode psychosis and chronic schizophrenia. Glutamine is produced in astrocytes following synaptic release of glutamate, and so has been suggested to be a marker of glutamatergic transmission. Studies in individuals at risk of psychosis, and patients with first-episode psychosis have found evidence of increased glutamatergic transmission in anterior cingulate and frontal cortex [Stone *et al.* 2009; Tibbo *et al.* 2004; Théberge *et al.* 2002; Bartha *et al.* 1997]. In contrast, studies of patients with chronic schizophrenia have generally found normal or reduced cortical glutamate levels [Ongur *et al.* 2009; Rowland *et al.* 2009; Tayoshi *et al.* 2009; Lutkenhoff *et al.* 2010; Ohrmann *et al.* 2005; Théberge *et al.* 2003; Block *et al.* 2000; Kegeles *et al.* 2000].

Subcortical measures of glutamate are less consistent. Individuals at risk of psychosis have been shown to have reduced thalamic glutamate levels [Stone, 2009], whereas patients with first-episode and chronic schizophrenia have been reported to have increased thalamic glutamine [Théberge *et al.* 2003, 2002]. The reason for

Figure 4. Reduced NMDA receptor binding in left hippocampus in drug free patients with schizophrenia and matched healthy controls [Pilowsky *et al.* 2006].

this discrepancy is not clear, but it may represent differences in imaging methodology, or possibly differences in illness subtype as increases in cortical glutamate release could be driven by reduced subcortical glutamatergic transmission on GABA interneurons or by dysfunctional NMDA receptors expressed on the same population of neurons [Olney and Farber, 1995].

There has been much speculation about how glutamate and dopamine may be related in schizophrenia, and whether glutamate or dopamine might be more ‘upstream’ in the illness. Olney and Farber hypothesized that glutamatergic changes might be related to a primary dopaminergic abnormality [Olney and Farber, 1995], whereas others have suggested that abnormalities in glutamate transmission or NMDA receptor function could drive changes in dopamine [Stone *et al.* 2007; Coyle, 2006; Harrison and Weinberger, 2005]. A plausible animal model of schizophrenia suggests that increased glutamate efferents from hippocampus may drive increased dopamine neuron responsivity [Lodge and Grace, 2006] (Figure 5). In support of this hypothesis, lower levels of hippocampal glutamate (potentially driving increased hippocampal outputs through reduced stimulation of GABA interneurons) are associated with increased striatal [18F]DOPA uptake (a marker of presynaptic dopamine function) in individuals with an ARMS

but not in healthy volunteers [Stone *et al.* 2010a]. The fact that this relationship was found in ARMS subjects and not in controls suggests GABA interneurons in individuals with an ARMS may be more sensitive to presynaptic glutamate levels, possibly due to lower hippocampal NMDA receptor expression [Pilowsky *et al.* 2006] (Figure 5). Drugs targeting glutamatergic transmission might help to normalize these deficits and have additional downstream effects on normalising dopamine neuron activity.

Drugs targeting glutamate abnormalities in schizophrenia: studies in patients

A number of different potential targets have been suggested to reverse the hypothesized abnormality of glutamatergic transmission in schizophrenia [Stone, 2009] (see Figure 6). These include i) enhancement of the function of NMDA receptors expressed on GABAergic interneurons: by increasing synaptic glycine levels, through direct action at the glycine_B site, or by mGlu5 receptor agonism; ii) enhancement of GABAergic interneuron function (through agonism of Trk1 receptors, alpha-7 nicotinic receptors or M1 receptors); iii) enhancement of GABA tone on glutamatergic projection neurons (through drugs with preferential effects at alpha-2 containing GABA receptors); and iv) reduction of the effect of excess downstream glutamate release by antagonism of AMPA glutamate receptors,

Figure 5. Reduced NMDA receptor (NMDAR) expression on hippocampal GABA interneurons leads to increased sensitivity to reductions in presynaptic glutamate levels and disinhibition of glutamate efferents from hippocampus (A) leading to enhanced stimulation of GABA neurons projecting from the nucleus accumbens (NAcc) to ventral pallidum (VP) resulting in enhanced inhibition of GABA neurons projecting from the VP to the ventral tegmental area (VTA) and disinhibition of dopamine (DA) neurons projecting to striatum [after Lodge *et al.* [2006]].

or by reducing glutamate release through agonism of mGlu2/3 autoreceptors (Figure 6).

Enhancement of NMDA receptor function

Several studies have investigated the effect of drugs which increase NMDA receptor function via the NMDA receptor glycine site: either increasing synaptic glycine levels by inhibiting type 1 glycine transporters (GlyT1) and preventing reuptake of synaptic glycine (sarcosine), or by acting as agonists at the glycine_B modulatory site (glycine and D-serine). As these compounds were not developed as CNS agents, relatively

high doses are required for a clinical response (30–60 g glycine per day has commonly been used). Nonetheless, a number of studies have employed these agents as adjunctive treatments in patients with schizophrenia. These have recently been reviewed in a meta-analysis, which showed a modest effect on both positive and negative psychotic symptoms [Tsai and Lin, 2010]. No trials of glycine_B agonists as monotherapy have been published to date, and it is possible that the effect size would be more marked when used as first-line treatment. A single study of sarcosine as monotherapy showed efficacy, but patients were randomized to low-dose (1 g) or high-doses (2 g) sarcosine and so a direct comparison against dopaminergic agents has not yet been made [Lane *et al.* 2008]. It is interesting to note that glycine, D-serine and sarcosine did not have any additional effect when added to clozapine [Tsai and Lin, 2010], possibly because part of the superior efficacy of clozapine may be due to intrinsic agonist action at the glycine_B modulatory site [Schwiler *et al.* 2008]. It must be noted that other currently available antipsychotic drugs (including haloperidol, thioridazine, chlorpromazine and clozapine) appear to interact with GlyT1 as noncompetitive antagonists at therapeutic doses [Williams *et al.* 2004].

Reduction of downstream glutamate release and its effects

Drugs enhancing the function of alpha-2 subunit containing GABA-A receptors should, theoretically, lead to reduced downstream glutamate release (Figure 6) [Lewis *et al.* 2005]. One study of MK-0777, a benzodiazepine-like drug with selectivity as a partial agonist at alpha-2 and alpha-3 GABA-A receptor subunits, reported improved cognition in patients with schizophrenia, but no effect on psychotic symptoms [Lewis *et al.* 2008].

Lamotrigine, a drug which inhibits glutamate release, has been investigated as an adjunctive treatment in schizophrenia. Lamotrigine has been shown to reverse positive, negative and cognitive symptoms associated with ketamine administration in healthy volunteers [Hosak and Libiger, 2002], and to reverse ketamine-associated changes in brain function measured using fMRI [Deakin *et al.* 2008]. A recent meta-analysis suggests that lamotrigine, in contrast to drugs acting through glycine enhancement of NMDA receptor function, is effective as

Figure 6. Potential targets for drugs to reduce excess cortical glutamate release: Enhancement of NMDA receptor function by direct action at glycine_B site [2], or by increasing synaptic glycine concentrations through the block of glycine transporters (1). Enhancement of NMDA receptor function through agonism of mGluR5 metabotropic glutamate receptors (3). Enhancement of GABA interneuron function through M1 or nicotinic alpha-7 agonism (4), or enhancement of BDNF function (5). Enhancement of GABA action on alpha-2 containing GABA-A receptors (6). Reduction of the effects of cortical glutamate release by blocking AMPA receptors (7), or by reducing glutamate release through mGlu2/3 autoreceptor agonism (8) [An earlier version of this figure appeared in Stone [2009]], reproduced with permission from Bentham Science Publishers Ltd.

an add-on medication for patients who are only partially responsive to clozapine, although effects were relatively modest [Tiihonen *et al.* 2009].

Glutamate mGlu 2/3 receptors are presynaptic autoreceptors [Kew and Kemp, 2005]. Agonists inhibit synaptic glutamate release (Figure 6), and have been shown to reduce the effects of NMDA receptor antagonists, and amphetamine in both animal and human studies [Javitt, 2004; Moghaddam, 2004]. A recent phase II trial of an mGlu2/3 receptor agonist (LY2140023, an oral prodrug of LY404039), in a sample of patients with chronic schizophrenia, reported significant improvement in positive and negative symptoms compared with placebo [Patil *et al.* 2007].

Olanzapine (15 mg daily) was used as an active control group in this study, and although not planned, a *post hoc* comparison of olanzapine versus LY2140023 revealed no statistically significant difference in terms of response to positive and negative symptoms. LY2140023 showed no propensity to elevated prolactin, weight gain or extrapyramidal side effects, however. Its main reported side effects were affective lability (although this was reported to be beneficial in some patients who had severe affective flattening leading to increased emotional response and spontaneous emotional fluctuations), and a mild reduction in body weight and body mass index. One curious feature of the study was that the group of patients on placebo showed no

improvement during the trial duration, whereas it is usual for improvement in symptomatology to be seen in patients in clinical trials on both placebo and active drug. A subsequent phase II trial of LY2140023 was reported by Lilly to be 'inconclusive' due to a large placebo response, with neither LY2140023 nor olanzapine showing a significant improvement over placebo. They also reported that convulsions occurred in 3 out of the 669 patients recruited [Kinon *et al.* 2010]. The study has not been published in full, and it is not clear whether Lilly plan to pursue further trials using this prodrug.

It has been suggested that mGlu2/3 agonists may work primarily through dopaminergic mechanisms [Seeman and Guan, 2009]. However, recent work reveals that the efficacy of mGlu2/3 agonists to block the effects of amphetamine, ketamine and PCP are lost in mGlu2/3 knockout mice [Fell *et al.* 2009]. It is possible that mGlu2/3 agonists may have downstream effects reducing D2High expression [Seeman *et al.* 2009]. Further studies of LY404039, LY2140023 and related compounds are awaited.

Topiramate, an antiepileptic drug with AMPA antagonist properties has been found to be effective as an adjunctive therapy in treatment-resistant patients with schizophrenia [Tiihonen *et al.* 2005], and to reduce the effects of MK-801 in rats [Deutsch *et al.* 2002], although it is possible that these effects of topiramate may occur through enhancement of GABA transmission, as AMPA antagonism only occurs at higher concentrations [Gibbs *et al.* 2000].

Other mechanisms

The antibiotic minocycline has, somewhat unexpectedly, been shown to inhibit the effects of NMDA receptor antagonism by MK-801 on rats [Levkovitz *et al.* 2007; Zhang *et al.* 2007], and to reverse PCP-induced cognitive deficits [Fujita *et al.* 2008]. A double-blind, randomized controlled trial of minocycline as add-on treatment in patients with early phase schizophrenia (within the first 5 years of diagnosis) revealed a significant effect on negative and cognitive symptoms [Levkovitz *et al.* 2010]. Although the exact mechanism of action for minocycline in schizophrenia has still to be ascertained, it is possible that its effect arises through the inhibition of glutamate excitotoxicity (mediated via nitric oxide) by blocking p38 MAP kinase and c-jun

N-terminal kinase (mitogen-activated protein kinases responsive to stress stimuli that regulate cellular functions including neurodegeneration, apoptosis, cell differentiation and proliferation) [Pi *et al.* 2004; Wilkins *et al.* 2004].

Cannabidiol (CBD), a constituent of cannabis, may also have a modulatory effect on glutamatergic transmission, as it has been shown to inhibit ketamine and MK-801-induced effects in animal models [Long *et al.* 2006; Moreira and Guimaraes, 2005], and in humans [Hallak *et al.* 2011]. Cannabis users with detectable levels of both CBD and delta-9 tetrahydrocannabinol (THC) in hair samples reported a lower incidence of schizophrenia-like symptoms than those in whom THC alone was detected [Morgan and Curran, 2008]. Furthermore, acute intoxication with cannabis containing low CBD led to impairments in recall, whereas high CBD cannabis did not induce any cognitive deficits [Morgan *et al.* 2010]. CBD has been shown to have the opposite effect to THC on neural activation measured using fMRI during an emotional processing task and a verbal memory task [Bhattacharyya *et al.* 2010; Fusar-Poli *et al.* 2009], and pretreatment with CBD significantly attenuates the psychotogenic effects of THC [Bhattacharyya *et al.* 2010; Karniol *et al.* 1974]. Preliminary work suggests that CBD is effective as an antipsychotic in patients with schizophrenia [Zuardi *et al.* 2006], although it had no additional beneficial effect in a small open-label study of clozapine-resistant patients [Zuardi *et al.* 2006].

The mechanism of action of CBD has not yet been elucidated completely. It has been demonstrated that CBD antagonizes the inhibitory effect of endocannabinoids and THC on GABA and glutamate transmission, mediated via CB1 receptors [Godino Mdel *et al.* 2007; Neu *et al.* 2007]. Given the hypothesized mechanism of ketamine action on GABA and glutamate systems, it is possible that the enhancement of GABA-A function is its primary mode of action in reducing ketamine-induced effects (Figure 6). However, a CB1 antagonist was not found to be effective in patients with schizophrenia [Meltzer *et al.* 2004], and there is growing evidence that some of the beneficial effects of CBD, like minocycline, may be mediated via inhibition of p38 MAP kinase [El-Remessy *et al.* 2008; Esposito *et al.* 2006].

Table 1. Glutamatergic drugs currently in development for the treatment of schizophrenia.

Company name	Drug name	Mechanism	Phase	Results
Roche	RG1678	GlyT1 inhibitor	Phase II	Effective vs. negative symptoms in patients with schizophrenia
Johnson & Johnson	R231857	GlyT1 inhibitor	Phase I	Improved scopolamine-induced cognitive impairments in healthy volunteers
Schering-Plough Lilly	Org 25935 LY379268	GlyT1 inhibitor Allosteric mGlu2 potentiator	?Phase II ?	No results in public domain Preclinical effectiveness vs. ketamine and MK-801 models
Merck	CDPPB	Allosteric mGlu5 potentiator	?	Preclinical effectiveness vs. amphetamine, MK-801 and sucrose-preference (negative symptoms) models

Drugs targeting glutamate in schizophrenia: drugs in development

GlyT1 inhibitors

Several pharmaceutical companies have published data on GlyT1 receptor inhibitors (see Table 1). Roche reported in a press release that their GlyT1 inhibitor, RG1678, was successful in treating negative symptoms in a phase II drug trial, but they have not published any further data on this compound at present [Pinard *et al.* 2010]. Johnson and Johnson have reported that the GlyT1 inhibitor, R231857, improved scopolamine-induced cognitive impairments in healthy volunteers [Liem-Moolenaar *et al.* 2010]. Schering-Plough report that they are investigating the effects of Org 25935 on negative symptoms, but no data have yet been released to the public domain. One concerning potential side effect of glycine transporter inhibitors is respiratory depression, although it is not clear whether this affects all compounds in this class [Perry *et al.* 2008]. Another issue is that the effect of GlyT1 inhibitors appears to occur only within a particular dose range, increasing NMDA receptor currents and long-term potentiation (LTP) within this range, but leading to reductions in NMDA receptor currents at higher doses [Martina *et al.* 2004].

Metabotropic glutamatergic receptors: allosteric potentiators

There has been some interest in developing allosteric potentiators of metabotropic glutamate receptors [Johnson *et al.* 2004], and two pharmaceutical companies have published data on these compounds (see Table 1). There are several theoretical advantages of allosteric potentiation in targeting the glutamatergic system.

As endogenous ligand is required for their action, they should have a lower propensity to side effects; they may also be less prone to desensitization which occurs with drugs targeting the active site. LY379268 is an allosteric drug potentiating glutamate signalling at the mGlu2 receptor currently in development by Lilly. It has been shown to block ketamine-induced glutamate release, as well as ketamine-induced dopamine and histamine release in the prefrontal cortex, and norepinephrine release in hippocampus [Fell *et al.* 2010; Lorrain *et al.* 2003a, 2003b]. It has also been shown to inhibit MK-801-induced retrosplenial cortex damage when injected into thalamus or cortex [Carter *et al.* 2004], suggesting that it may be neuroprotective in the early stages of psychosis.

3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is an allosteric potentiator of the mGlu5 receptor developed by Merck [Lindsley *et al.* 2004]. It increases the affinity of glutamate for the receptor, leading to an enhancement of NMDA receptor activity (Figure 6). It has been shown to attenuate amphetamine-induced PPI deficits [Kinney *et al.* 2005], and to reverse MK-801-induced elevation in pyramidal cell activity [Lecourtier *et al.* 2007]. It was also effective in an animal model of negative symptoms (MK-801-induced impairment of sucrose preference) [Vardigan *et al.* 2010], and showed superior efficacy compared with mGlu2/3 agonists in reversing MK-801-induced cognitive impairment [Vales *et al.* 2010; Stefani and Moghaddam, 2010]. CDPPB was found to have a U-shaped dose–response curve on cognitive function and on GluR1 phosphorylation, however, suggesting a fairly tight therapeutic window [Uslaner *et al.* 2009].

Glutamate and illness progression in schizophrenia: a critical window of opportunity?

Elevated cortical glutamate activity in schizophrenia appears to be most marked in the early phases of the illness [Théberge *et al.* 2002] and in the prodrome [Stone *et al.* 2009]. Thus, it makes intuitive sense that drugs targeting excess glutamate release may be of most benefit when given during these stages. Indeed, as the illness progresses, it appears that, rather than being overactive, that cortical glutamate system may be reduced in function compared with healthy volunteers [Théberge *et al.* 2003]. It is tempting to speculate that administration of drugs that reduce cortical glutamate release (such as mGlu2/3 agonists), or inhibit its effects (such as AMPA antagonists and possibly minocycline) may be disease-modifying if given early enough, preventing transition to psychosis in individuals with prodromal symptoms and improving outcome in individuals with first-episode schizophrenia.

The evidence for a phase-specific deficit in NMDA receptor function is less clear, however. In one small SPECT study with the NMDA receptor ligand [123I]CNS-1261, unmedicated individuals with chronic schizophrenia were shown to have reduced NMDA receptor binding in left hippocampus [Pilowsky *et al.* 2006]. Thus, drugs targeting NMDA receptor enhancement (glycine_B agonists, GlyT1 antagonists and mGlu5 receptor agonists) may be of benefit at other phases of the illness including the prodrome and first episode.

Clearly further work is required to investigate these hypotheses as trials to date have generally targeted individuals with chronic schizophrenia.

Conclusions

Novel drugs targeting glutamate transmission have shown considerable promise in the treatment of schizophrenia. Current evidence supports their use as adjunctive agents in individuals who fail to respond to conventional dopaminergic antipsychotic drugs, and preliminary data suggests that they are also efficacious as monotherapy. There are currently a large number of glutamatergic compounds in development, with a great deal of excitement about their potential as novel therapeutic agents in schizophrenia. It seems likely that the next wave of drugs for schizophrenia will target this system.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

Dr Stone was employed on a non-restricted academic fellowship by GlaxoSmithKline 2008–2009. He has received travel expenses for conference attendance from Janssen. He has received honoraria from Berenberg Bank and from Pfizer.

References

- Addington, J., Addington, D. and Maticka-Tyndale, E. (1991) Cognitive functioning and positive and negative symptoms in schizophrenia. *Schizophrenia Res* 5: 123–134.
- Andreasen, N.C. (1999) A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. *Arch Gen Psychiatry* 56: 781–787.
- Bartha, R., Williamson, P.C., Drost, D.J., Malla, A., Carr, T.J., Cortese, L. *et al.* (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. *Arch Gen Psychiatry* 54: 959–965.
- Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T. *et al.* (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. *Neuropsychopharmacology* 35: 764–774.
- Bilder, R.M., Reiter, G., Bates, J., Lencz, T., Szeszko, P., Goldman, R.S. *et al.* (2006) Cognitive development in schizophrenia: follow-back from the first episode. *J Clin Exp Neuropsychol* 28: 270–282.
- Block, W., Bayer, T.A., Tepest, R., Traber, F., Rietschel, M., Muller, D.J. *et al.* (2000) Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. *Neurosci Lett* 289: 147–151.
- Buchanan, R.W., Breier, A., Kirkpatrick, B., Ball, P. and Carpenter Jr, W.T. (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. *Am J Psychiatry* 155: 751–760.
- Carter, K., Dickerson, J., Schoepp, D.D., Reilly, M., Herring, N., Williams, J. *et al.* (2004) The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. *Neuropharmacology* 47: 1135–1145.
- Coyle, J.T. (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. *Cellular Mol Neurobiol* 26: 365–384.

- Deakin, J.F., Lees, J., McKie, S., Hallak, J.E., Williams, S.R. and Dursun, S.M. (2008) Glutamate and the neural basis of the subjective effects of ketamine: a pharmacological-magnetic resonance imaging study. *Arch Gen Psychiatry* 65: 154–164.
- Deutsch, S.I., Rosse, R.B., Billingslea, E.N., Bellack, A.S. and Mastroianni, J. (2002) Topiramate antagonizes MK-801 in an animal model of schizophrenia. *Eur J Pharmacol* 449: 121–125.
- Dingledine, R., Borges, K., Bowie, D. and Traynelis, S.F. (1999) The glutamate receptor ion channels. *Pharmacol Rev* 51: 7–61.
- El-Remessy, A.B., Tang, Y., Zhu, G., Matragoon, S., Khalifa, Y., Liu, E.K. *et al.* (2008) Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. *Mol Vision* 14: 2190–2203.
- Esposito, G., De Filippis, D., Maiuri, M.C., De Stefano, D., Carnuccio, R. and Iuvone, T. (2006) Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. *Neurosci Lett* 399: 91–95.
- Fell, M.J., Katner, J.S., Johnson, B.G., Khilevich, A., Schkeryantz, J.M., Perry, K.W. *et al.* (2010) Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge. *Neuropharmacology* 58: 632–639.
- Fell, M.J., Perry, K.W., Falcone, J.F., Johnson, B.G., Barth, V.N., Rash, K.S. *et al.* (2009) In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicarboxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268). *J Pharmacol Exp Therapeutics* 331: 1126–1136.
- Fujita, Y., Ishima, T., Kunitachi, S., Hagiwara, H., Zhang, L., Iyo, M. *et al.* (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. *Progress Neuro-psychopharmacol Biol Psychiatry* 32: 336–339.
- Fusar-Poli, P., Crippa, J.A., Bhattacharyya, S., Borgwardt, S.J., Allen, P., Martin-Santos, R. *et al.* (2009) Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. *Arch Gen Psychiatry* 66: 95–105.
- Gibbs III, J.W., Sombati, S., DeLorenzo, R.J. and Coulter, D.A. (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. *Epilepsia* 41(Suppl. 1): S10–S16.
- Godino Mdel, C., Torres, M. and Sanchez-Prieto, J. (2007) CB1 receptors diminish both Ca(2+) influx and glutamate release through two different mechanisms active in distinct populations of cerebrocortical nerve terminals. *J Neurochem* 101: 1471–1482.
- Hallak, J.E., Dursun, S.M., Bosi, D.C., de Macedo, L.R., Machado-de-Sousa, J.P., Abreu, J. *et al.* (2011) The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. *Progress Neuro-psychopharmacol Biol psychiatry* 35(1): 198–202.
- Harrison, P.J. and Weinberger, D.R. (2005) Schizophrenia genes, gene expression, and neuropsychology: on the matter of their convergence. *Mol Psychiatry* 10: 40–68.
- Hosak, L. and Libiger, J. (2002) Antiepileptic drugs in schizophrenia: a review. *Eur Psychiatry* 17: 371–378.
- Javitt, D.C. (2001) Management of negative symptoms of schizophrenia. *Curr Psychiatry Rep* 3: 413–417.
- Javitt, D.C. (2004) Glutamate as a therapeutic target in psychiatric disorders. *Mol Psychiatry* 9: 984–997, 979.
- Javitt, D.C. (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine–glutamate Interactions. *Int Rev Neurobiol* 78: 69–108.
- Johnson, M.P., Nisenbaum, E.S., Large, T.H., Emkey, R., Baez, M. and Kingston, A.E. (2004) Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. *Biochem Soc Trans* 32: 881–887.
- Kane, J., Honigfeld, G., Singer, J. and Meltzer, H. (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 45: 789–796.
- Kapur, S. and Mamo, D. (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. *Prog Neuropsychopharmacol Biol Psychiatry* 27(7): 1081–1090.
- Karniol, I.G., Shirakawa, I., Kasinski, N., Pfeifferman, A. and Carlini, E.A. (1974) Cannabidiol interferes with the effects of delta 9 -tetrahydrocannabinol in man. *Eur J Pharmacol* 28: 172–177.
- Kegeles, L.S., Shungu, D.C., Anjilvel, S., Chan, S., Ellis, S.P., Xanthopoulos, E. *et al.* (2000) Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. *Psychiatry Res* 98: 163–175.
- Kew, J.N. and Kemp, J.A. (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. *Psychopharmacology* 179: 4–29.
- Kinney, G.G., O'Brien, J.A., Lemaire, W., Burno, M., Bickel, D.J., Clements, M.K. *et al.* (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. *J Pharmacol Exp Therapeutics* 313: 199–206.

- Kinon, B.J., Zhang, L., Williams, J.E., Osuntokun, O.O., Millen, B.A. and Kollack-Walker, S. (2010) Ly2140023 monohydrate: an agonist at the Mglu2/3 receptor for the treatment of schizophrenia. *Schizophrenia Res* 117: 379–379.
- Krystal, J.H., Perry Jr, E.B., Gueorguieva, R., Belger, A., Madonick, S.H., Abi-Dargham, A. *et al.* (2005) “Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function”. *Arch Gen Psychiatry* 62(9): 985–994.
- Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D. *et al.* (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Arch Gen Psychiatry* 51: 199–214.
- Lane, H.Y., Liu, Y.C., Huang, C.L., Chang, Y.C., Liao, C.H., Perng, C.H. *et al.* (2008) Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. *Biol Psychiatry* 63: 9–12.
- Law, A.J. and Deakin, J.F. (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. *Neuroreport* 12: 2971–2974.
- Lecourtier, L., Homayoun, H., Tamagnan, G. and Moghaddam, B. (2007) Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. *Biol Psychiatry* 62: 739–746.
- Levkovitz, Y., Levi, U., Braw, Y. and Cohen, H. (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. *Brain Res* 1154: 154–162.
- Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G. *et al.* (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. *J Clin Psychiatry* 71: 138–149.
- Lewis, D.A., Cho, R.Y., Carter, C.S., Eklund, K., Forster, S., Kelly, M.A. *et al.* (2008) Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. *Am J Psychiatry* 165: 1585–1593.
- Lewis, D.A., Hashimoto, T. and Volk, D.W. (2005) Cortical inhibitory neurons and schizophrenia. *Nat Rev Neurosci* 6: 312–24.
- Liem-Moolenaar, M., Zoethout, R.W., de Boer, P., Schmidt, M., de Kam, M.L., Cohen, A.F. *et al.* (2010) The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. *J Psychopharmacol* 24: 1681–1687.
- Lindsley, C.W., Wisnoski, D.D., Leister, W.H., O’Brien, J.A., Lemaire, W., Williams Jr, D.L. *et al.* (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide derivatives that potentiate receptor function in vivo. *J Med Chem* 47: 5825–5828.
- Lodge, D.J. and Grace, A.A. (2006) The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. *Neuropsychopharmacology* 31: 1356–61.
- Long, L.E., Malone, D.T. and Taylor, D.A. (2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. *Neuropsychopharmacology* 31: 795–803.
- Lorrain, D.S., Baccei, C.S., Bristow, L.J., Anderson, J.J. and Varney, M.A. (2003a) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. *Neuroscience* 117: 697–706.
- Lorrain, D.S., Schaffhauser, H., Campbell, U.C., Baccei, C.S., Correa, L.D., Rowe, B. *et al.* (2003b) Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. *Neuropsychopharmacology* 28: 1622–1632.
- Lutkenhoff, E.S., van Erp, T.G., Thomas, M.A., Therman, S., Manninen, M. *et al.* (2010) Proton MRS in twin pairs discordant for schizophrenia. *Mol Psychiatry* 15(3): 308–318.
- Martina, M., Gorfinkel, Y., Halman, S., Lowe, J.A., Periyalwar, P., Schmidt, C.J. *et al.* (2004) Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. *J Physiol* 557: 489–500.
- McEvoy, J.P., Lieberman, J.A., Stroup, T.S., Davis, S.M., Meltzer, H.Y., Rosenheck, R.A. *et al.* for the CATIE Investigators. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 163: 600–610.
- Meltzer, H.Y., Arvanitis, L., Bauer, D. and Rein, W. for the Meta-Trial Study Group. (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. *Am J Psychiatry* 161: 975–984.
- Moghaddam, B. (2004) Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. *Psychopharmacology (Berl)* 174: 39–44.
- Moghaddam, B., Adams, B., Verma, A. and Daly, D. (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive

- disruptions associated with the prefrontal cortex. *J Neurosci* 17: 2921–2927.
- Moreira, F.A. and Guimaraes, F.S. (2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. *Eur J Pharmacol* 512: 199–205.
- Morgan, C.J. and Curran, H.V. (2006) Acute and chronic effects of ketamine upon human memory: a review. *Psychopharmacology* 188: 408–424.
- Morgan, C.J. and Curran, H.V. (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. *Br J Psychiatry* 192: 306–307.
- Morgan, C.J., Schafer, G., Freeman, T.P. and Curran, H.V. (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. *Br J Psychiatry* 197: 285–290.
- Neu, A., Foldy, C. and Soltesz, I. (2007) Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at cholecystikinin-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus. *J Physiol* 578: 233–247.
- Ohrmann, P., Siegmund, A., Suslow, T., Spitzberg, K., Kersting, A., Arolt, V. *et al.* (2005) Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. *Schizophr Res* 73: 153–157.
- Olney, J.W. and Farber, N.B. (1995) Glutamate receptor dysfunction and schizophrenia. *Arch Gen Psychiatry* 52: 998–1007.
- Olney, J.W., Newcomer, J.W. and Farber, N.B. (1999) NMDA receptor hypofunction model of schizophrenia. *J Psychiatr Res* 33: 523–533.
- Ongur, D., Prescott, A.P., Jensen, J.E., Cohen, B.M. and Renshaw, P.F. (2009) Creatine abnormalities in schizophrenia and bipolar disorder. *Psychiatry Res* 172: 44–48.
- Patil, S.T., Zhang, L., Martenyi, F., Lowe, S.L., Jackson, K.A., Andreev, B.V. *et al.* (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. *Nat Med* 13: 1102–1107.
- Perry, K.W., Falcone, J.F., Fell, M.J., Ryder, J.W., Yu, H., Love, P.L. *et al.* (2008) Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. *Neuropharmacology* 55: 743–754.
- Phillips, L.J., Yung, A.R. and McGorry, P.D. (2000) Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. *Aust N Z J Psychiatry* 34(Suppl): S164–S169.
- Pi, R., Li, W., Lee, N.T., Chan, H.H., Pu, Y., Chan, L.N. *et al.* (2004) Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. *J Neurochem* 91: 1219–1230.
- Pilowsky, L.S., Bressan, R.A., Stone, J.M., Erlandsson, K., Mulligan, R.S., Krystal, J.H. *et al.* (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. *Mol Psychiatry* 11: 118–119.
- Pinard, E., Alanine, A., Alberati, D., Bender, M., Borroni, E., Bourdeaux, P. *et al.* (2010) Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfon-yl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. *J Medicinal Chem* 53: 4603–4614.
- Rothman, D.L., Behar, K.L., Hyder, F. and Shulman, R.G. (2003) In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. *Annu Rev Physiol* 65: 401–427.
- Rowland, L.M., Spieker, E.A., Francis, A., Barker, P.B., Carpenter, W.T. and Buchanan, R.W. (2009) White matter alterations in deficit schizophrenia. *Neuropsychopharmacology* 34: 1514–1522.
- Schwieler, L., Linderholm, K.R., Nilsson-Todd, L.K., Erhardt, S. and Engberg, G. (2008) Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. *Life Sci* 83: 170–175.
- Seeman, P., Battaglia, G., Corti, C., Corsi, M. and Bruno, V. (2009) Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. *Synapse* 63: 247–251.
- Seeman, P. and Guan, H.C. (2009) Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor. *Synapse* 63: 935–939.
- Seeman, P. and Lee, T. (1975) Antipsychotic drugs: direct correlation between clinical potency and pre-synaptic action on dopamine neurons. *Science* 188: 1217–1219.
- Sharp, F.R., Tomitaka, M., Bernaudin, M. and Tomitaka, S. (2001) Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? *Trends Neurosci* 24: 330–334.
- Stefani, M.R. and Moghaddam, B. (2010) Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. *Eur J Pharmacol* 639: 26–32.
- Stone, J.M. (2009) Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. *Curr Pharmaceut Design* 15: 2594–2602.
- Stone, J.M., Day, F., Tsagaraki, H., Valli, I., McLean, M.A., Lythgoe, D.J. *et al.* (2009) Glutamate dysfunction in people with prodromal symptoms of

- psychosis: relationship to gray matter volume. *Biol Psychiatry* 66: 533–539.
- Stone, J.M., Erlandsson, K., Arstad, E., Squassante, L., Teneggi, V., Bressan, R.A. *et al.* (2008) Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study. *Psychopharmacology (Berl)* 197: 401–408.
- Stone, J.M., Howes, O.D., Egerton, A., Kambeitz, J., Allen, P., Lythgoe, D.J. *et al.* (2010a) Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. *Biol Psychiatry* 68: 599–602.
- Stone, J.M., Morrison, P.D. and Pilowsky, L.S. (2007) Glutamate and dopamine dysregulation in schizophrenia—a synthesis and selective review. *J Psychopharmacol* 21: 440–452.
- Stone, J.M., Raffin, M., Morrison, P. and McGuire, P.K. (2010b) Review: The biological basis of antipsychotic response in schizophrenia. *J Psychopharmacol* 24: 953–964.
- Tamminga, C.A., Buchanan, R.W. and Gold, J.M. (1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. *Int Clin Psychopharmacol* 13(Suppl. 3): S21–S26.
- Tayoshi, S., Sumitani, S., Taniguchi, K., Shibuya-Tayoshi, S., Numata, S., Iga, J. *et al.* (2009) Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). *Schizophrenia Res* 108: 69–77.
- Théberge, J., Al-Semaan, Y., Williamson, P.C., Menon, R.S., Neufeld, R.W.J., Rajakumar, N. *et al.* (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. *Am J Psychiatry* 160: 2231–2233.
- Théberge, J., Bartha, R., Drost, D.J., Menon, R.S., Malla, A., Takhar, J. *et al.* (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. *Am J Psychiatry* 159: 1944–1946.
- Tibbo, P., Hanstock, C., Valiakalayil, A. and Allen, P. (2004) 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. *Am J Psychiatry* 161: 1116–1118.
- Tiihonen, J., Halonen, P., Wahlbeck, K., Repo-Tiihonen, E., Hyvarinen, S., Eronen, M. *et al.* (2005) Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. *J Clin Psychiatry* 66: 1012–1015.
- Tiihonen, J., Wahlbeck, K. and Kiviniemi, V. (2009) The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. *Schizophrenia Res* 109: 10–14.
- Tsai, G.E. and Lin, P.Y. (2010) Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. *Curr Pharm Des* 16(5): 522–537.
- Uslaner, J.M., Parmentier-Batteur, S., Flick, R.B., Surles, N.O., Lam, J.S., McNaughton, C.H. *et al.* (2009) Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. *Neuropharmacology* 57: 531–538.
- Vales, K., Svoboda, J., Benkovicova, K., Bubenikova-Valesova, V. and Stuchlik, A. (2010) The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801. *Eur J Pharmacol* 639: 91–98.
- Vardigan, J.D., Huszar, S.L., McNaughton, C.H., Hutson, P.H. and Uslaner, J.M. (2010) MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? *Pharmacol Biochem Behavior* 95: 223–229.
- Ventura, J., Helleman, G.S., Thames, A.D., Koellner, V. and Nuechterlein, K.H. (2009) Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. *Schizophrenia Res* 113: 189–199.
- Wilkins, A., Nikodemova, M., Compston, A. and Duncan, I. (2004) Minocycline attenuates nitric oxide-mediated neuronal and axonal destruction in vitro. *Neuron Glia Biol* 1: 297–305.
- Williams, J.B., Mallorga, P.J., Jeffrey Conn, P., Pettibone, D.J. and Sur, C. (2004) Effects of typical and atypical antipsychotics on human glycine transporters. *Schizophr Res* 71(1): 103–112.
- Zhang, L., Shirayama, Y., Iyo, M. and Hashimoto, K. (2007) Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. *Neuropsychopharmacology* 32: 2004–2010.
- Zuardi, A.W., Crippa, J.A., Hallak, J.E., Moreira, F.A. and Guimaraes, F.S. (2006) Cannabidiol, a *Cannabis sativa* constituent, as an antipsychotic drug. *Braz J Med Biol Res* 39: 421–429.